PF-Atlas › Clinical Trials › NCT05538585
A Study to Assess How Food Affects the Safety and Pharmacokinetics of Galicaftor and Navocaftor
Galicaftor · Phase 1
Registry ID
NCT05538585
Phase
Phase 1
Status
Completed
Drug / intervention
Galicaftor
Sponsor
AbbVie
Start
2022-09-27
Enrollment
24
Locations
2
About this trial
Cystic Fibrosis (CF) is a rare, life-threatening, genetic disease that affects the lungs and digestive system, significantly impairing the quality of life, with those affected having a median age of death at 40. The objectives of this study are to assess the effect of food on the safety and pharmacokinetics of navocaftor and galicaftor.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT05538585 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.